Yale partners up to run medical device trials

Like many top-tier schools, Yale University has a wealth of expertise and capability in clinical research, and now, citing demand for medical device studies, the Ivy League institution has teamed up with a CRO to land more trial contracts.

The Yale Cardiovascular Research Group (YCRG), the school's on-campus clinical service provider, has teamed up with Belgian CRO Genae. The pair plans to share and subcontract monitoring, regulatory, safety, core laboratory, data management and statistical analysis services for clients, working across all phases of development.

YCRG bills itself as an academic research organization, offering trial design, core lab and regulatory support, among other services. Group Director Alexandra Lansky said partnering with a traditional CRO was the ideal next step for YCRG, as demand for high-quality but cost-effective research continues to grow.

"This unique ARO/CRO collaboration takes advantage of the opportunities of sponsored clinical trials to advance scientific understanding and to promote a broad application of evidence-based medicine that will ultimately benefit patients," Lansky said in a statement. "It combines the need for academic vision and guidance with the need for partners that have an entrepreneurial approach, scalable capabilities and financial backing to invest for the future."

Yale is hardly the first academic institution to lend its know-how to contract research work. Rutgers, West Virginia University and Texas Tech have all launched in-house CROs, and Duke University has thus far found the most success with the model, signing study deals through its well-respected Clinical Research Unit.

- read the announcement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.